Shared instrumentation represents a institute-wide resource set up with modular locations to serve each of the CCSG Programs. Modular resources are housed in the Grace Cancer Drug Center (Therapeutics), Cell and Virus (Cancer Genetics and Mouse Molecular Genetics), and the Cancer Cell Center (Immunology). Mot of the equipment included within this resource is represented by those items common to most types of biomedical research. There are several objectives in maintaining shared instrumentation. Centralized support of this resource ensures continuous access to equipment commonly used by a variety of investigators conducting peer reviewed research and to allow access to those investigators applying for such support. Centralized equipment ensures maximum utilization and therefore cost efficiency of research dollars. Equipment included in the shared instrumentation resource is generally lumped together for service contract agreements. The inclusion of multiple pieces of equipment on the same service contract allow for discounted rates, stability of service contract agreements and minimization of disrupts due to equipment breakdown. Shared instrumentation also increases the availability of high-end equipment (e.g., ultracentrifuges, densitometers, imaging equipment) for which support by traditional individual investigator type funding (e.g., RO1 type support) is difficult to obtain. The shared instrumentation resource, in addition to allowing investigators to have access to a reliable facility for conducting a multitude of essential but conventional type studies, but also can allow investigators to take advantage of newly developed technology that requires equipment not generally supported by individual investigator awards.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016056-26
Application #
6452245
Study Section
Project Start
2001-05-07
Project End
2003-04-30
Budget Start
Budget End
Support Year
26
Fiscal Year
2001
Total Cost
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Rossetti, Stefano; Wierzbicki, Andrzej J; Sacchi, Nicoletta (2018) Undermining ribosomal RNA transcription in both the nucleolus and mitochondrion: an offbeat approach to target MYC-driven cancer. Oncotarget 9:5016-5031
Block, Matthew S; Vierkant, Robert A; Rambau, Peter F et al. (2018) MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clin Proc 93:307-320
Li, Qiuhui; Deng, Qu; Chao, Hsueh-Ping et al. (2018) Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses. Nat Commun 9:3600
Kawaguchi, Tstutomu; Yan, Li; Qi, Qianya et al. (2018) Novel MicroRNA-Based Risk Score Identified by Integrated Analyses to Predict Metastasis and Poor Prognosis in Breast Cancer. Ann Surg Oncol 25:4037-4046
Mett, V; Komarova, E A; Greene, K et al. (2018) Mobilan: a recombinant adenovirus carrying Toll-like receptor 5 self-activating cassette for cancer immunotherapy. Oncogene 37:439-449
Long, Mark D; Singh, Prashant K; Russell, James R et al. (2018) The miR-96 and RAR? signaling axis governs androgen signaling and prostate cancer progression. Oncogene :
Hirose, Yuki; Nagahashi, Masayuki; Katsuta, Eriko et al. (2018) Generation of sphingosine-1-phosphate is enhanced in biliary tract cancer patients and is associated with lymphatic metastasis. Sci Rep 8:10814
Vexler, Albert; Yu, Jihnhee; Zhao, Yang et al. (2018) Expected p-values in light of an ROC curve analysis applied to optimal multiple testing procedures. Stat Methods Med Res 27:3560-3576
Mussell, Ashley L; Denson, Kayla E; Shen, He et al. (2018) Loss of KIBRA function activates EGFR signaling by inducing AREG. Oncotarget 9:29975-29984
Yendamuri, Sai; Groman, Adrienne; Miller, Austin et al. (2018) Risk and benefit of neoadjuvant therapy among patients undergoing resection for non-small-cell lung cancer. Eur J Cardiothorac Surg 53:656-663

Showing the most recent 10 out of 1555 publications